



CIN: L24100GJ1984PLC111413

Reg. Office: 1-5th Floor, Aditraj Arcade, Nr Karma Shreshtha Tower, 100 Ft Rd, Satellite, Ahmedabad - 380015.

Date: 14th February, 2026

To,

Listing Compliances, BSE Limited, P. J. Towers, Fort, Mumbai - 400001. Scrip Code: 539938; Scrip Id: MIL	Listing Compliances, CSE - India, 7, Lyons Range, Dalhousie Kolkata - 700001.
--	---

Subject: Outcome of Board Meeting and Compliances of Regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Dear Sir/Ma'am,

Pursuant to provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., February 14, 2026, inter alia, considered and approved Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended on December 31, 2025 along with Limited review report issued by M/s. V Goswami & Co, Statutory Auditors of the Company.

Further, please find enclosed "Standalone and Consolidated unaudited Financial Results along with Limited Review Report" for the quarter and nine months ended on December 31, 2025 as **Annexure 1** and same is also available on the website of the Company viz. www.medicointercontinental.com

The Board Meeting of the Company commenced at 12:30 PM and concluded at 12:55 PM.

This is for your information and records.

Thanking You,

FOR MEDICO INTERCONTINENTAL LIMITED



Samir D Shah
Managing Director
(DIN: 03350268)



V.GOSWAMI & CO.
CHARTERED ACCOUNTANTS

RBI UCN NO. :- 897783
C&AG REG NO. :- WR4659
MSME :- GJ01D0134595
GST :- 24AAHFV3075F1Z7

3, SF, Manek Appt, Nr. Jain Derasar, B/s. Tagor Park, Nehrunagar Circle, Ahmedabad - 380015.
M : +91 94287 33430, +91 97247 28711 | E-mail : thegoswami@gmail.com | www.goswami.in

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended)

TO THE BOARD OF DIRECTORS OF **MEDICO INTERCONTINENTAL LIMITED**

We have reviewed the accompanying Statements of Standalone Unaudited Financial Results of MEDICO INTERCONTINENTAL LIMITED ("the company") , for the quarter ended December 31, 2025 ("the Statement") and year to date from April 01,2025 to December 31,2025 ("the Statement") , being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity ', issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





V.GOSWAMI & CO.
CHARTERED ACCOUNTANTS

RBI UCN NO. :- 897783
C&AG REG NO. :- WR4659
MSME :- GJ01D0134595
GST :- 24AAHFV3075F1Z7

3, SF, Manek Appt, Nr. Jain Derasar, B/s. Tagor Park, Nehrunagar Circle, Ahmedabad - 380015.
M : +91 94287 33430, +91 97247 28711 | E-mail : thegoswami@gmail.com | www.goswami.in

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, V. GOSWAMI & CO,
Chartered Accountants
(FRN: 0128769W)

Vipul Goswami
(Partner)

Mem No: 119809

Date: - 14/02/2026

Place:-Ahmedabad

UDIN: 26119809ZPIKBQ1327



MEDICO INTERCONTINENTAL LIMITED							
CIN NO : L24100GJ1984PLC111413							
Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE NR KARMA, SHRESHTHA TOWER, 100 FT RD, SATELLITE, Ahmedabad GJ 380015 IN							
Tel No. 079-26742739		E-mail:- mail@medicointercontinental.com			Website: www.medicointercontinental.com		
Statement of Standalone Unaudited Financial Results for the Quarter and nine months ended December 31, 2025							
(Rs In LAKHS)							
Sr. No.	Particulars	Quarter Ended			Nine months ended		Year Ended
		3 Months ended	Preceding 3 Months ended	Corresponding 3 months ended in previous year on	Year to date figure for current period ended	Year to date figure for previous period ended	Previous Year ended
		31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Revenues						
1	Revenue from Operations	1275.12	1241.95	1142.82	3863.74	5188.54	6712.98
2	Other Income	79.32	58.05	17.37	161.56	37.48	50.77
3	Total Revenue (A)	1354.44	1300.00	1160.19	4025.31	5226.02	6763.75
	Expenses						
(a)	Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
(b)	Purchases of stock-in-trade	1201.71	1029.78	961.76	3179.43	4047.63	5444.92
(c)	Changes in inventories of finished goods and stock-in-trade	-96.97	12.96	-16.50	44.50	243.85	162.74
(d)	Employee benefits expense	72.85	56.13	45.41	179.86	120.37	174.06
(e)	Finance costs	38.53	44.90	16.75	126.951	44.12	67.22
(f)	Depreciation and amortisation expense	17.25	18.71	17.29	53.52	34.84	55.57
(g)	Other expenses	36.73	56.99	60.25	202.48	447.06	501.68
	Total Expenses (B)	1270.10	1219.46	1084.96	3786.74	4937.87	6406.20
5	Profit/(Loss) before exceptional items & tax (1-4)	84.34	80.54	75.23	238.56	288.15	357.55
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) for the period from operations before tax (5+6)	84.34	80.54	75.23	238.56	288.15	357.55
8	Tax expense	23.19	21.35	20.57	62.61	84.88	100.97
(a)	Current Tax	22.61	21.53	19.83	63.85	77.96	94.44
(b)	Deferred Tax	0.58	-0.18	0.74	-1.24	6.92	6.54
9	Profit/(Loss) for the period from continuing operations (7-8)	61.15	59.19	54.66	175.95	203.27	256.58
10	Profit/(loss) for the period from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) for the period from Discontinued operations (after tax)	0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/ (loss) for the period (After tax)	61.15	59.19	54.66	175.95	203.27	256.58
14	Other Comprehensive Income						0.00
15	Total Comprehensive Income for the period (13+14)	61.15	59.19	54.66	175.95	203.27	256.58
	Paid-up Equity Share Capital (Face Value INR 10 each)	1000.00	1000.00	1000.00	1000.00	1000.00	1000.00
16	Earnings Per Equity Share of Rs. 10 each (for continuing Operations)						
(a)	(Basic) - INR	0.61	0.59	0.55	1.76	2.03	2.57
(b)	(Diluted) - INR	0.61	0.59	0.55	1.76	2.03	2.57
17	Earnings Per Equity Share of Rs. 10 each (for discontinuing Operations)						
(a)	(Basic) - INR	0.000	0.00	0.000	0.000	0.000	0.000
(b)	(Diluted) - INR	0.000	0.00	0.000	0.000	0.000	0.000
18	Earnings Per Equity Share of Rs. 10 each (for continuing & discontinuing Operations)						
(a)	(Basic) - INR	0.61	0.59	0.55	1.76	2.03	2.57
(b)	(Diluted) - INR	0.61	0.59	0.55	1.76	2.03	2.57

- The above unaudited standalone financial results of the Company for the quarter and nine months ended December 31,2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 14, 2026. The above results reviewed by statutory auditors and who have expressed an unmodified opinion on these results.
- These results have been prepared in accordance with the Ind AS notified under the Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
- During the quarter ended December 31, 2025 , the company is operating in single segment . So segment reporting is not applicable for this quarter, but segment information shall provides as and when the same shall be operative.
- The Company has continued with old Income Tax rates for the current quarter and is evaluating option available under section 115 BAA of the Income Tax Act, 1961 as per the Taxation Laws (Amendment) Ordinance, 2019 .
- The previous period figures have been re-grouped / reclassified, wherever considered necessary.

For, Medico Intercontinental Limited

TANVI SHAH
Chairperson
DIN:08192047



Place: Ahmedabad
Date: 14/02/2026



3, SF, Manek Appt, Nr. Jain Derasar, B/s. Tagor Park, Nehrunagar Circle, Ahmedabad - 380015.
M : +91 94287 33430, +91 97247 28711 | E-mail : thegoswami@gmail.com | www.goswami.in

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended)

TO THE BOARD OF DIRECTORS OF **MEDICO INTERCONTINENTAL LIMITED**

We have reviewed the accompanying Statements of Consolidated Unaudited Financial Results of MEDICO INTERCONTINENTAL LIMITED ("the Parent ") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended December 31, 2025 ("the Statement") and year to date from April 01, 2025 to December 31, 2025 attached herewith , being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity ', issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Parent Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.





V. GOSWAMI & CO.
CHARTERED ACCOUNTANTS

RBI UCN NO. :- 897783

C&AG REG NO. :- WR4659

MSME :- GJ01D0134595

GST :- 24AAHFV3075F1Z7

3, SF, Manek Appt, Nr. Jain Derasar, B/s. Tagor Park, Nehrunagar Circle, Ahmedabad - 380015.
M : +91 94287 33430, +91 97247 28711 | E-mail : thegoswami@gmail.com | www.goswami.in

The Statement included the results of following subsidiary and joint venture company:-

1. EVAGRACE PHARMA PRIVATE LIMITED
2. RITZ FORMULATIONS PRIVATE LIMITED
3. SUNGRACE PHARMA PRIVATE LIMITED
4. AZILLIAN HEALTHCARE PRIVATE LIMITED
5. CALBORN LIFESCIENCE PRIVATE LIMITED
6. MEDICO LAB (Joint Venture)

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the interim financial results of the subsidiaries and joint venture included in the consolidated unaudited financial results, whose financial results and other unaudited financial information, total revenues of Rs. 1098.88 Lakhs and Rs.3431.52 Lakhs and total net profit Rs -226.45 Lakhs and Rs.-1040.74 Lakhs for quarter ended December 31, 2025 and for the period from April 01, 2025 to December 31, 2025, respectively, as considered in the Statement whose financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors for CALBORN LIFESCIENCE PRIVATE LIMITED and for other subsidiaries and joint venture by management whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiaries, is based solely on the reports of the other auditors and management and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of these matters.

For, V. GOSWAMI & CO,
Chartered Accountants
(FRN:0128769W)

Vipul Goswami
(Partner)

Mem No:119809

Date :-14/02/2026

Place :- Ahmedabad

UDIN: 26119809WMMGSYK7102



MEDICO INTERCONTINENTAL LIMITED							
CIN NO: L24100GJ1984PLC111413							
Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE NR KARMA SHRESHTHA TOWER, 100 FT RD, SATELLITE, Ahmedabad GJ 380015 IN							
Tel No. 079-26742739		E-mail:- mail@medicointercontinental.com		Website: www.medicointercontinental.com			
Statement of Consolidated Unaudited Financial Results for the Quarter and nine months ended December 31, 2025							
(Rs in Lakhs)							
Sr. No.	Particulars	Quarter Ended			Nine months Ended		Year Ended
		3 Months ended 31.12.2025 Unaudited	Preceding 3 Months ended 30.09.2025 Unaudited	Corresponding 3 months ended in previous year on 31.12.2024 Unaudited and Restated	Year to date figure for current period ended 31.12.2025 Unaudited	Year to date figure for previous period ended 31.12.2024 Unaudited and Restated	Previous Year ended 31.03.2025 Audited and Restated
	Revenues						
1	Revenue from Operations	1984.84	2039.55	1842.78	6159.88	7415.89	9531.53
2	Other Income	34.17	55.41	13.41	115.89	30.66	41.71
3	Total Revenue (A)	2019.01	2094.96	1856.18	6275.76	7446.54	9573.23
4	Expenses						
	(a) Cost of materials consumed	131.46	242.16	0.00	534.70	0.00	0.00
	(b) Purchases of stock-in-trade	1528.59	1286.98	1466.84	4104.17	5445.04	7252.23
	(c) Changes in inventories of finished goods and stock-in-trade	-224.70	146.46	-61.26	80.33	317.60	192.24
	(d) Employee benefits expense	236.95	218.58	126.38	651.25	327.40	465.99
	(e) Finance costs	189.78	205.76	23.52	631.26	69.39	99.31
	(f) Depreciation and amortisation expense	142.77	195.41	22.81	400.05	51.04	78.69
	(g) Other expenses	154.11	234.14	120.77	652.62	701.39	802.66
	Total Expenses (B)	2158.96	2529.49	1699.06	7054.38	6911.86	8891.12
5	Profit/(Loss) before exceptional items & tax (1-4)	-139.95	-434.52	157.12	-778.61	534.68	682.11
6	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) for the period from operations before tax (5+6)	-139.95	-434.52	157.12	-778.61	534.68	682.11
8	Tax expense	28.40	19.34	43.69	95.23	153.70	186.59
	(a) Current Tax	45.01	46.63	41.47	133.48	142.31	175.44
	(b) Deferred Tax	-16.61	-27.29	2.22	-38.25	11.39	11.15
9	Profit/(Loss) for the period from continuing operations (7-8)	-168.35	-453.87	113.44	-873.85	380.99	495.53
10	Share of Profit/ (Loss) of Associates and Joint Ventures	3.06	3.17	3.97	9.06	7.97	10.20
11	Profit After Tax and Share of Profit/ (Loss) of Associates and Joint Ventures for the period from continuing operations (9+10)	-165.29	-450.70	117.40	-864.79	388.95	505.73
12	Profit/(loss) for the period from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
13	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
14	Profit/(loss) for the period from Discontinued operations (after tax)	0.00	0.00	0.00	0.00	0.00	0.00
15	Profit/ (loss) for the period (After tax)	-165.29	-450.70	117.40	-864.79	388.95	505.73
16	Other Comprehensive Income						
	(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to item that will not be reclassified to	0.00	0.00	0.00	0.00	0.00	0.00
	(B) (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to item that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	Other comprehensive Income/(Loss)	0.00	0.00	0.00	0.00	0.00	0.00
17	Total Comprehensive Income for the period (13+14)	-165.294	-450.70	117.40	-864.79	388.95	505.73
	Net profit attributable to:						
	Owners of the holding company	-21.78	-165.152	117.40	-254.76	388.95	505.73
	Non-controlling interest	-143.51	-285.548	0.00	-610.03	0.00	0.00
	Other comprehensive income attributable to:						
	Owners of the holding company	0.00	0.00	0.00	0.00	0.00	0.00
	Non-controlling interest	0.00	0.00	0.00	0.00	0.00	0.00
	Total comprehensive income attributable to:						
	Owners of the holding company	-21.78	-165.15	117.40	-254.76	388.95	505.73
	Non-controlling interest	-143.51	-285.55	0.00	-610.03	0.00	0.00
18	Paid-up Equity Share Capital (Face Value INR 10 each)	1000.000	1000.000	1000.000	1000.000	1000.000	1000.00
19	Earnings Per Equity Share of Rs. 10 each (for Continuing Operations)						
	(a) Basic - INR	-0.22	-1.65	1.17	-2.55	3.89	5.06
	(b) Diluted - INR	-0.22	-1.65	1.17	-2.55	3.89	5.06
20	Earnings Per Equity Share of Rs. 10 each (for Discontinuing Operations)						
	(a) Basic - INR	0.000	0.000	0.000	0.000	0.000	0.00
	(b) Diluted - INR	0.000	0.000	0.000	0.000	0.000	0.00
21	Earnings Per Equity Share of Rs. 10 each (for Continuing & Discontinuing Operations)						
	(a) Basic - INR	-0.22	-1.65	1.17	-2.55	3.89	5.06
	(b) Diluted - INR	-0.22	-1.65	1.17	-2.55	3.89	5.06

For, Medico Intercontinental Limited

TANVI SHAH
Chairperson
DIN:08192047



Place:- Ahmedabad
Date:- 14/02/2026

NOTES - CONSOLIDATED

1 The above unaudited consolidated financial results of the Company for the quarter and nine month ended as on 31st December, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 14, 2026. The above results reviewed by statutory auditors and who have expressed an unmodified opinion on these results.

2 During the quarter and nine month ended as on 31st December, 2025 the company is operating in single segment. So, segment reporting is not applicable for this quarter, but segment information shall be provided when it applicable.

3 The key standalone financial information of the Company is given below:

Particulars	Quarter ended			Half year ended		Year ended
	31/12/2025	30/09/2025	31/12/2024	31/12/2025	31/12/2024	31/03/2025
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from operations	1354.44	1300.00	1160.19	4025.31	5226.02	6763.75
Profit before tax	84.34	80.54	75.23	238.56	288.15	357.55
Net profit after tax	61.15	59.19	54.66	175.95	203.27	256.58
Total comprehensive income	61.15	59.19	54.66	175.95	203.27	256.58

4. During the quarter ended June 30, 2025, the Group has changed its accounting policy for investments in joint venture (MEDICO LAB). Previously, the Group accounted for joint venture using the proportionate consolidation method. Effective Q1 2025-26, the Group has adopted the equity method of accounting for investments in joint ventures, in accordance with Ind AS 28 "Investments in Associates and Joint Ventures."

The change in accounting policy has been applied retrospectively and the corresponding comparative figures for the previous periods have been restated to ensure comparability, as required under Ind AS 8 "Accounting Policies, Changes in Accounting Estimates and Errors."

This change is effective from April 01, 2025, and as a result, the Group has ceased proportionate consolidation of MEDICO LAB and now recognizes its investment as a single line item in the consolidated balance sheet and its share of profit or loss in the consolidated income statement

To reflect this change and maintain comparability, prior period figures have been

* T *Tanish*



restated. The table below summarizes the quantitative impact on the Group's consolidated financial statements for the year ended 31st March 2025:

Restated Comparative Figures as below

(Rs. In Lakhs)									
Particulars	Q3 FY 2024-25			Half year (Q1+Q2+Q3) FY 2024-25			FY 2024-25		
	As Previously Reported	Effect of Restatement	As Restated	As Previously Reported	Effect of Restatement	As Restated	As Previously Reported	Effect of Restatement	As Restated
Revenue	1926.21	-70.03	1856.18	7490.10	-43.56	7446.54	9637.12	-63.89	9573.23
Expenses	1763.98	-64.92	1699.06	6945.10	-33.24	6911.86	8939.80	-48.68	8891.12
Profit after Tax	117.40	-3.97	113.43	388.95	-7.97	380.98	505.73	-10.20	495.53
Share of Profit/(loss) form Joint Venture			3.97			7.97			10.20

5. The previous period figures have been re-grouped / reclassified, wherever considered necessary, to make them comparable.

For, Medico Intercontinental Limited



TANVI SHAH
Chairperson
DIN: 08192047



Place: Ahmedabad
Date: -14/02/2026